Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
J&J Eyes Double-Digit Growth in Japan Pharma Biz from 2027, 50 Approvals by 2029
Johnson & Johnson’s Innovative Medicine unit aims to snag around 50 regulatory approvals in Japan by 2029, looking to rack up double-digit growth in local pharma sales from 2027 and onwards, company executives told the...
To read the full story
Related Article
- J&J Japan Targets Top Share in Key Disease Areas by 2030: New President
November 12, 2025
- J&J Makes Debut in Japan Lung Cancer Market with Rybrevant Launch
December 2, 2024
BUSINESS
- GSK Files Hep B Drug in Japan as First Global Submission
February 27, 2026
- Astellas Doubles Labor Productivity Since FY2020, Credits Organization Rejig
February 27, 2026
- Sumitomo Regains DSP-0187 Rights as Jazz Calls Off Deal
February 27, 2026
- Asahi Kasei to Buy German Antiviral Specialist Aicuris for 143.1 Billion Yen
February 27, 2026
- Daiichi Sankyo Chair Manabe to Step Down in June
February 27, 2026
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…